血清VEGF、TSGF及CA125对浸润性膀胱癌患者预后的预测价值

doi:10.19558/j.cnki.10-1020/r.2020.06.009

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (982 KB) RICH HTML
输出: BibTeX | EndNote (RIS)

摘要 目的： 探讨血清血管内皮生长因子（VEGF）、肿瘤特异性生长因子（TSGF）及糖类抗原125（CA125）对浸润性膀胱癌（IBC）患者预后的预测价值。方法： 选取118例接受经尿道等离子电切术的IBC患者为研究对象,分析不同临床特征患者血清VEGF、TSGF及CA125水平差异。根据患者治疗结束后5年的预后情况分为生存组（86例）和死亡组（32例）,研究影响预后的相关因素,探讨VEGF、TSGF及CA125对IBC患者预后的预测价值。结果： 不同肿瘤分期、病理分级和有无转移患者血清VEGF、TSGF及CA125水平差异有统计学意义（P<0.05）,与生存组相比,死亡组中T₃期、高级别和转移患者比例相对较高,死亡组血清VEGF、TSGF、CA125水平也显著升高（P<0.05）。多因素分析显示,肿瘤分期、病理分级、有无转移和血清VEGF、TSGF、CA125的表达情况是影响IBC患者预后的重要危险因素（P<0.05）。血清VEGF、TSGF、CA125预测患者不良预后的AUC分别为0.848、0.818、0.825,血清VEGF、TSGF及CA125高表达患者5年生存率显著低于低表达患者（P<0.05）。结论： 血清VEGF、TSGF及CA125的表达与IBC的临床特征及预后有关,检测血清VEGF、TSGF及CA125水平对IBC的预后判断具有参考价值。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	胡金鼎
	张建军
	闫会秋
	徐亚光
	石汝骥
	程镇
	汪生辉

关键词 ：膀胱癌, 预后, 血管内皮生长因子, 肿瘤特异性生长因子, 糖类抗原125

Abstract：Objective： To investigate the prognostic value of vascular endothelial growth factor （VEGF）, tumor-specific growth factor （TSGF） and carbohydrate antigen 125 （CA125） in patients with invasive bladder cancer （IBC）. Methods： A total of 118 IBC patients undergoing transurethral plasma electrotomy were selected as subjects. The differences in serum VEGF, TSGF and CA125 levels in patients with different clinical characteristics were analyzed. The patients were divided into a survival group （86 cases） and a death group （32 cases） according to their 5-year prognosis after treatment. The risk factors that affected the prognosis were studied. The prognostic value of VEGF, TSGF and CA125 in patients with IBC was investigated. Results： There were statistically significant differences in serum VEGF, TSGF and CA125 levels among patients with different tumor stages, pathological grades and with or without metastasis （P < 0.05）. Compared with the survival group, the proportion of patients with stage T3, high grade and metastasis in death group was significantly increased, and the serum levels of VEGF, TSGF and CA125 in death group were also significantly increased （P < 0.05）. Multivariate analysis showed that tumor stage, pathological grade, metastasis and the expression of VEGF, TSGF and CA125 were important risk factors for the prognosis of patients with IBC （P < 0.05）. The AUC of serum VEGF, TSGF and CA125 predicting poor prognosis of patients was 0.848, 0.818 and 0.825, respectively. The 5-year survival rate of patients with high serum VEGF, TSGF and CA125 levels was significantly lower than in those with low levels （P < 0.05）. Conclusion： The levels of VEGF, TSGF and CA125 are related to the clinical features and prognosis of patients with IBC. The levels of VEGF, TSGF and CA125 can be used to predict the prognosis of IBC.

Key words： bladder cancer prognosis vascular endothelial growth factor tumor-specific growth factor carbohydrate antigen 125

收稿日期: 2020-02-27

ZTFLH:

R737.35

通讯作者: 胡金鼎,hujinding1982@163.com

引用本文:

胡金鼎, 张建军, 闫会秋, 徐亚光, 石汝骥, 程镇, 汪生辉. 血清VEGF、TSGF及CA125对浸润性膀胱癌患者预后的预测价值[J]. 微创泌尿外科杂志, 2020, 9(6): 400-405.
HU Jinding, ZHANG Jianjun, YAN Huiqiu, XU Yaguang, SHI Ruji, CHENG Zhen, WANG Shenghui. Predictive value of serum VEGF, TSGF and CA125 for prognosis in patients with invasive bladder cancer. JOURNAL OF MINIMALLY INVASIVE UROLOGY, 2020, 9(6): 400-405.

链接本文:

http://journal20.magtechjournal.com/Jwk_zgmnwk/CN/abstract/abstract1637.shtml 或 http://journal20.magtechjournal.com/Jwk_zgmnwk/CN/Y2020/V9/I6/400

[1] ROBERTSON AG, KIM J, AL-AHMADIE HA, et al.Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell, 2017,171(3):540.
[2] SMITH AB, JAEGER B, PINHEIRO LC, et al.Impact of bladder cancer on health-related quality of Life. BJU Int, 2018,121(4):549-557.
[3] 郑元振. 血清血管内皮生长因子、细胞角蛋白19片段与浸润性膀胱癌患者预后的关系.中国临床医生杂志,2017,45(11):55-58.
[4] HIMBERT C, OSE J, LIN TD, et al.Inflammation- and angiogenesis-related biomarkers are correlated with cancer-related fatigue in colorectal cancer patients: Results from the ColoCare Study. Eur J Cancer Care (Engl), 2019,28(4,SI):e13055.
[5] PANER GP, STADLER WM, HANSEL DE, et al.Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers. Eur Urol, 2018,73(4):560-569.
[6] SPIESS PE, AGARWAL N, BANGS R, et al.Bladder cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw, 2017,15(10):1240-1267.
[7] ANTONI S, FERLAY J, SOERJOMATARAM I, et al.Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol, 2017,71(1):96-108.
[8] ÖZAYDIN Ş, ATAŞ E, KARADURMUŞ N, et al.Outcomes of bladder preservation therapy on survival in patients with muscle-invasive bladder cancer. Arch Esp Urol, 2020,73(1):41-46.
[9] BAZARGANI ST, CLIFFORD TG, DJALADAT HA, et al.Association between precystectomy epithelial tumor marker response to neoadjuvant chemotherapy and oncological outcomes in urothelial bladder cancer. Urol Oncol, 2019,37(1):1-11.
[10] LI K, XU YZ, TAN MY, et al.A retrospective comparison of Thulium laser en bloc resection of bladder tumor and plasmakinetic transurethral resection of bladder tumor in primary non-muscle invasive bladder cancer. Lasers Med Sci, 2019,34(1):85-92.
[11] 杨洪波,石洁,叶勇,等.COL5 A2在膀胱癌组织中的表达及其与临床病理特征和预后的相关性分析.实用肿瘤学杂志,2019,33(1):52-56.
[12] KIM SH, SONG MK, JY J, et al.Significant clinicopathologic prognostic factors for bladder recurrence, progression, and cancer-specific survival after surgery among patients with upper urinary tract urothelial carcinoma. Investig Clin Urol, 2019,60(6):432-442.
[13] 林晨,刘湘鄂,向俊,等.吡柔比星膀胱灌注对浅表性膀胱癌患者血清sICAM-1、VEGF及MMP-9水平的影响.微创泌尿外科杂志,2018,7(5):346-350.
[14] 陈铁定,鲁特飞,张鹏.膀胱癌患者血清血小板因子4的表达及临床意义.中国现代医学杂志,2019,29(22):118-122.
[15] 母健君,白冰,张天德,等.腹腔镜膀胱癌根治术的临床疗效及对患者血清SF,SIL-2R及TSGF水平的影响.现代生物医学进展,2017,17(24):4695-4698.
[16] SHAO TR, HUANG JX, ZHENG ZA, et al.SCCA, TSGF, and the long non-coding RNA AC007271.3 are effective biomarkers for diagnosing oral squamous cell carcinoma. Cell Physiol Biochem, 2018,47(1):26-38.
[17] BUDAK E, SOLAKOGLU KD, BUDAK A, et al.The prognostic significance of serum CA125 levels with ER, PR, P53 and Ki-67 expression in endometrial carcinomas. Ginekol Pol, 2019,90(12):675-683.
[18] DOCHEZ V, CAILLON H, VAUCEL E, et al.Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. J Ovarian Res, 2019,12(1):28.